Apomorphine treatment is a key unmet need for PD sufferers in India. King’s is bringing their expertise and knowledge to address this gap in treatment offered in India.

Parkinson’s disease (PD) is generally seen as a movement disorder caused by degeneration of some brain structures and decreased dopamine. Current therapies focus mainly on the classic motor symptoms (such as shaking, stiffness and slowness of movement) and include mainly dopaminergic drugs like levodopa and dopamine agonists. One of these agonists is Apomorphine and is currently prescribed only for patients at advanced stages of PD where conventional drug therapies are no longer sufficient.

King’s is one of the leading centres in the UK providing this therapy. Prof K Ray Chaudhuri is a leading clinician and facilitator of introducing Apomorphine in India. King’s is sharing their Centre of Excellence expertise and provides clinical and academic training for the teams joining the Apomorphine pathway project.

Apomorphine Inaugural Launch - Kolkata, India, 4th - 5th January 2019

Prof Chuadhuri with Dr Vinod Metta in conjunction with King’s College London and the Parkinson Foundation Centre of Excellence at King’s College Hospital hosted inaugural launching of advanced therapy for PD in the form of Apomorhine injection and infusion with widespread media coverage in key cities in India. Excerpts are taken from the 4-5 jan meeting in Kolkata India. Apomorphine treatment is a key unmet need for thousands of PD sufferers in India.


This novel initiative aims to create world’s first international observational database focusing on patients treated with Apomorphine, in a unique collaboration between King’s and India as well as the Middle East.

To date, there has been no such collaborations across the world in Parkinson’s Disease. We hope this will act as a platform for many more such partnerships in future.

Our research coordinators responsible for this international work are Aleksandra and Dhaval.